Ciliary neurotrophic factor receptor alpha subunit (CNTFRα)

Ciliary neurotrophic factor receptor alpha subunit (CNTFRα) is a ligand-binding component of the tripartite CNTF receptor complex, serving as the primary binding partner for ciliary neurotrophic factor (CNTF) and allowing signal propagation via recruitment of signal-transducing components gp130 and leukemia inhibitory factor receptor (LIFR)[2][3][5][7][8]. The alpha subunit is a glycosylphosphatidylinositol-anchored membrane protein predominantly expressed in neural tissues but also found in some non-neural cells, such as certain liver and cancer cells[2][8][9]. The receptor is essential for the biological effects of CNTF, including promoting neuronal survival, regulating glucose metabolism, and modulating cell cycle progression. CNTFRα is closely related to the interleukin-6 receptor family[7], and research suggests it can mediate responses to other cytokines such as cardiotrophin-like cytokine (CLC)[3][5][9]. Altered expression or function of CNTFRα has been implicated in neurodegenerative diseases, liver cancer, glioma, and certain metabolic disorders. NT-501, an experimental encapsulated cell therapy releasing CNTF for retinal degeneration, is an example of a therapy indirectly acting through this receptor[4]. Direct small-molecule or antibody drugs targeting CNTFRα are not established in current clinical practice.

Other names

Ciliary neurotrophic factor receptor subunit alphaCNTFRCNTFR-alpha

Activates downstream pathways (e.g., JAK/STAT, MAPK, PI3K/AMPK) upon ligand (CNTF) binding; Supports neuronal survival by complex formation with gp130 and leukemia inhibitory factor receptor (LIFR); Modulates glucose uptake through increased GLUT4 translocation in metabolic tissues